ADVERTISEMENT
Search
Login JOIN / RENEW

Transitions Magazine

Transitions is published bi-monthly for members of the APhA New Practitioner Network. The online newsletter contains information focused on life inside and outside pharmacy practice, providing guidance on various areas of professional, personal, and practice development. Each issue includes in-depth articles on such topics as personal financial management, innovative practice sites, career profiles, career development tools, residency and postgraduate programs, and more.

FDA: Don’t use antibody testing to evaluate immunity after COVID-19... FDA: Don’t use antibody testing to evaluate immunity after COVID-19...

FDA: Don’t use antibody testing to evaluate immunity after COVID-19...

0 19321

FDA reminded health care professionals and the public that results from currently authorized COVID-19 antibody tests should not be used to assess a person’s level of immunity or protection from COVID-19 at any time, particularly after the person has received a COVID-19 vaccination.

Preventing VTE in critically ill COVID-19 patients Preventing VTE in critically ill COVID-19 patients

Preventing VTE in critically ill COVID-19 patients

Venous thromboembolism (VTE) is the most commonly reported thrombotic complication of COVID-19, with approximately 28% of critically ill patients...
0 18749
Dexamethasone appears safe in preventing postsurgery nausea Dexamethasone appears safe in preventing postsurgery nausea

Dexamethasone appears safe in preventing postsurgery nausea

Although dexamethasone is often used to prevent nausea and vomiting after surgery, concerns have been raised that it may increase the risk of...
0 19155

ISMP updates COVID-19 vaccine errors

The Institute for Safe Medication Practices (ISMP) continues to track the errors that have been reported from the currently authorized COVID-19 vaccines.

FDA approves higher dosage of naloxone nasal spray

On April 30, FDA announced the approval of a higher dosage of naloxone hydrochloride nasal spray (Kloxxado—Hikma Pharmaceuticals) to treat opioid overdose. The newly approved product delivers 8 mg of naloxone into the nasal cavity, compared with previously approved 2- and 4-mg naloxone nasal spray products.
123456789
ADVERTISEMENT